Old Post Office, Barcelona

What started out as a short update from the recent EORTC-NCI-AACR (ENA / Triple Meeting) in Barcelona on new data in the KRAS niche turned out to be a much more in-depth review in light of the explosion of corporate interest in this area.

At this meeting several companies provided updates on compounds, which either recently entered the clinic or were imminent, including the very first KRAS G12D degrader to make it past IND enabling studies. We also saw initial data for many new drugs on the horizon, including some in discovery or preclinical development. There were definitely some gems to be found in the poster hall!

If you didn’t make it to Barcelona for what turned out to be one of the most informative Triple meetings of recent years then this piece is for you if you’re following the burgeoning KRAS space.

In this post we highlight and discuss various direct KRAS approaches, as well as indirect upstream (SHP2), downstream (MEK, ERK, and ULK), and even cross-stream (PI3K) targets of interest.  KRAS G12C inhibitors were just a start, while the future may well look quite different…

To continue reading our latest discussion on oncology new product development plus expert commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by